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Background: Leishmaniasis is a protozoan disease, affecting 12 million people in different 
regions of the world with a wide spectrum of diseases. Although several chemotherapeutic agents 
have been used for treating the disease, long-term therapy, limited efficacy and the development 
of drug-resistant parasites remain the major limitations.
Methods: To develop a new nanovaccine for leishmaniasis, recombinant Leishmania superoxide 
dismutase (SODB1) was loaded onto chitosan nanoparticles by the ionotropic gelation 
method. Size and loading efficiency of the nanoparticles were evaluated and optimized, and 
an immunization study was undertaken on BALB/c mice. The mice received phosphate buffer 
saline (PBS), superoxide dismutase B1 (SODB1) in PBS and nanoparticles via subcutaneous 
injection. Soluble Leishmania Antigens (SLA) and complete Freund’s adjuvant (CFA) were 
also injected subcutaneously three times every three weeks (some groups received only a single 
dose). Three weeks after the last injection, blood samples were collected and assessed with 
ELISA to detect IgG2a and IgG1.
Results: Immunological analysis showed that in single and triple doses of SODB1 nanoparticles, 
IgG2a and IgG2a/IgG1 were significantly higher than the other groups (P<0.05).
Conclusion: The results revealed that formulations of SODB1 in biodegradable and stable 
chitosan nanoparticles can increase the immunogenicity toward cell-mediated immunity (TH1 
cells producing IgG2a in mice) that is effective in Leishmania eradication and could be presented 
as a single dose nanovaccine for leishmaniasis.
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Introduction
Leishmaniasis is a vector-transmitted protozoan disease distributed throughout the 
world’s tropical and subtropical regions. Leishmaniasis is caused by 20 different species 
which are pathogenic to humans, and belong to the genus Leishmania, an intracellular 
parasite transmitted by the bite of the phlebotomine sandfly. Leishmaniasis currently 
threatens 350 million people in 88 countries around the world. Two million new 
cases are considered to occur annually, with an estimated 12 million people presently 
infected.1–3 There is also a growing number of cases of human immunodeficiency virus 
(HIV)/leishmaniasis coinfection. Leishmaniasis is an important opportunistic infection 
in HIV patients, which is potentially fatal, even when treated   appropriately. HIV infec-
tion can also increase the risk of development of visceral leishmaniasis by 10–100-fold 
in endemic areas.4 Leishmaniasis is a parasitic disease with a wide range of clinical International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  presentations, including cutaneous, mucocutaneous, and vis-
ceral. The most dangerous form of leishmaniasis is kala-azar 
which, if untreated, has a fatality rate as high as 100% within 
two years in developing countries.5 Although several thera-
peutic agents, including paromomycin, antimony-containing 
compounds, amphotericin B, fluconazole, and pentamidine, 
are used as drug therapy in leishmaniasis, the need for 
prolonged regimens, drug-induced adverse effects, limited 
efficacy, development of drug-resistant parasite species, and   
scarring the skin remain important limitations of leishma-
niasis drug therapy programs.2 On the other hand, immuno-
therapy could be able to prevent the infection, and an effective 
vaccine for leishmaniasis would be an effective means of 
eradication of this infectious protozoan disease.
Although many efforts have been made to formulate a 
Leishmania vaccine during the last decade, effective immu-
notherapy against leishmaniasis has not yet been achieved.3,6 
First-generation vaccines against leishmaniasis consisted 
of dead parasites. A vaccine comprising a single dose of 
whole-cell autoclave-killed Leishmania major was mixed 
with Bacillus Calmette–Guérin (BCG) vaccine and com-
pared with BCG vaccine alone against leishmaniasis in Bam, 
Iran.7 However, this vaccine was shown to have low efficacy 
(54%). Second-generation vaccines used the antigen subunits 
of the parasite which were naive fractions purified from 
parasites or synthetic antigens made by DNA recombinant 
  technology. Third-generation vaccines include genes coding 
for a protective antigen and cloned into a vector containing 
a eukaryotic promoter. Recombinant second-generation 
vaccines and third-generation DNA vaccines achieved mean 
parasite load reductions of 68% and 59%, respectively, in 
laboratory animal models, but their success in field trials 
has not yet been reported.8 The first recombinant antigen 
used to vaccinate against leishmaniasis was leishmaniolysin 
(gp63), a membrane protease present in the promastigotes of 
all   species, but its immunogenic properties in clinical trials 
were shown to be limited.9
In the present study, recombinant Leishmania superoxide 
dismutase B1 (SODB1), an antigen cloned in Iran, was tested 
as another potential antigen for immunotherapy.10 L. major 
SODB1 is a 195-amino acid protein with a molecular weight 
of 21287 Da and an isoelectric pH of 6.31. Superoxide dis-
mutases are a group of metalloenzymes that eliminate super-
oxide radicals by dismutation into hydrogen peroxide and 
molecular oxygen. Typically, eukaryotes, including mam-
mals, have Cu/ZnSOD in the cytosol and MnSOD in the 
mitochondrial matrix, whereas FeSODs have been found 
in prokaryotes and protozoa, and in the chloroplasts of 
plants and algae. Two closely related FeSODs (ie, SODB1 
and SODB2), have been identified in Leishmania chagasi, 
  localized within the glycosomes in high levels, and have been 
found to play an important role in the survival and growth 
of Leishmania within human macrophages.11,12
Unfortunately most protein and peptide vaccines show 
only low immunological activity when administered alone. 
Incorporation of antigens with adjuvants can improve the 
immunological response. Previous studies confirm that use 
of adjuvants increases the efficacy of purified antigens by up 
to 82% in vaccines.8 However, the most effective adjuvants, 
eg, Freund’s adjuvant, generally cause severe inflamma-
tion, which may preclude their use in humans because of 
  unacceptable side effects.13
Particulate delivery of antigen is effective for increasing 
the immunogenicity of vaccine subunits used in combination 
with an adjuvant. Moreover, phagocytosis of the particles 
by macrophages are important for induction of TH1 and 
TH2 responses, probably by affecting initial antigen uptake, 
processing, and presentation.14
In the present study, chitosan was used as an adjuvant 
nanoparticulate delivery system for the SODB1 vaccine 
subunit. Chitosan, α(1-4)2-amino 2-deoxy β-D glucan, is 
a deacetylated form of chitin, a polysaccharide present in 
abundance in the shells of crustaceans.15 The cationic nature of 
chitosan has been conveniently exploited for the development 
of particulate drug delivery systems. In addition to its ability 
to complex with negatively charged polymers, an interesting 
property of chitosan is its ability to form a gel on contact 
with specific polyanions. Ionotropic gelation of chitosan with 
tripolyphosphate for drug encapsulation was first reported by 
Bodmeier et al,16 although their approach aimed at designing 
chitosan-tripolyphosphate beads rather than nanoparticles.
Another benefit of nanoparticulate delivery of SODB1 is 
sustained release of the antigen and ongoing stimulation of 
the immune system. Therefore, the possibility of developing a 
single-dose vaccine could be examined. Also, the main problem 
with antigens, ie, lack of stability and loss of potency during 
handling and transportation, suggesting potentially severe prob-
lems with future scale up of recombinant vaccine production, 
could be overcome by the increased stability of a nanoparticle 
formulation. Therefore, scale up of this formulation and subunit 
vaccines with GMP compliance could be possible.
Materials and methods
Materials
Chitosan (high, medium, and low molecular weight), 
and complete Freund’s adjuvant were purchased from International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  Sigma-Aldrich (St Louis, MO). Tripolyphosphate, bovine 
serum albumin, Coomassie Brilliant Blue G250, and gla-
cial acetic acid were purchased from Merck Chemicals 
(Darmstadt, Germany). Recombinant SODB1 was kindly 
donated by the Autoimmune Diseases Research Center of 
Shiraz University of Medical Sciences. Rabbit antimouse 
IgG1 horseradish peroxidase conjugate and goat antimouse 
IgG2a horseradish peroxidase conjugate were purchased 
from Invitrogen (Carlsbad, CA). Tetramethylbenzidine was 
purchased from Zymed Laboratories (South San Francisco, 
CA). Ultrapure water was used during the all experiments 
(Direct Q3; Millipore Iberica, Madrid, Spain). All other 
chemicals were of pharmaceutical grade.
Female BALB/c mice (4–6 weeks of age) were purchased 
from the Razi Research Institute for Vaccine and Serum 
in Iran. Each group of mice was kept in a separate cage, 
with access to water and food under stress-free conditions, 
in the animal house of the Shiraz University of Medical 
Sciences.
Preparation of chitosan nanoparticles
Chitosan nanoparticles were prepared according to the 
ionotropic gelation process.17,18 Low, medium, and high 
molecular weight chitosan was dissolved in 0.25% (v/v) 
acetic acid solution (by mixing at 1500 rpm for two hours) to 
make chitosan concentrations of 0.05, 0.10, 0.20, 0.30, 0.50, 
and 0.60% (w/v). Different concentrations of tripolyphos-
phate solutions in purified water (from 0.02%–2.5%) were 
added dropwise to the chitosan solution under magnetic 
stirring at room temperature. Formation of the nanopar-
ticles was the result of interaction between the negatively 
charged groups of tripolyphosphate and the positively 
charged amino groups of the chitosan. The nanoparticle 
suspensions were gently stirred for 60 minutes at room 
temperature before being subjected to further analysis or 
application.19,20 Selected concentrations of chitosan and 
tripolyphosphate which produced appropriate nanoparticles 
were used to fabricate SODB1-loaded nanoparticles by the 
same method, except that SODB1 solution was incorporated 
into tripolyphosphate solution prior to being added to the 
chitosan solution. In each SODB1 loading experiment, 
1 mL of solution containing 2 mg SODB1 was added to 
tripolyphosphate solution. The zeta potential of the nano-
particles was assessed (Zetasizer; Malvern Instruments, 
Malvern, UK) in optimized SODB1-loaded chitosan nano-
particles. The preparation procedure and administration of 
the   vaccine in the animal model are presented schematically 
in Figure 1.
characterization of nanoparticles
A laser defraction particle size analyzer (SALD 2101; 
  Shimadzu, Tokyo, Japan) was used to measure the mean 
diameter and size distribution of the nanoparticles. 
  Morphological examination of the nanoparticles was per-
formed by transmission electron microscopy (CM10; Philips, 
  Eindhoven, The Netherlands). The samples were stained with 
2% (w/v) phosphotungstic acid and placed on copper grids 
with Formvar films, to be viewed by transmission electron 
microscopy.
evaluation of protein-loading  
in nanoparticles
The nanoparticles were separated from the solution by 
ultracentrifugation at 50,000 g and at 10°C for 30 minutes. 
Supernatant from the centrifugation was carefully separated, 
and the protein content in the supernatant was analyzed with 
ultraviolet spectrophotometry at 595 nm using the indirect 
Bradford protein assay. A calibration curve was plotted 
with five different concentrations of bovine serum albumin 
as the standard protein for constructing the standard curve. 
Triplicate samples were analyzed at each time interval, and 
the loading efficiency in chitosan-loaded nanoparticles was 
calculated from the calibration curve. The loading efficiency 
of the SODB1 nanoparticles was calculated according to the 
following formula:
% LE =
 SODB1(total)   SODB1 (free amount in supernatant)
 SO
− 
D DB1(total)
×100
Immunization study
Sixty female BALB/c mice were divided into 12 groups, and 
5 µg/50 µL of SODB1 was injected subcutaneously via the 
scruff of the neck in three doses at three-weekly intervals 
based on guidelines provided in other papers describing similar 
research.21,22 All of the injections were prepared under aseptic 
conditions under laminar air flow, and put into insulin syringes 
(31 gauge, 12.7 mm in length). The different groups of animals 
receiving the vaccine are summarized in Table 1.
Chitosan TPP SODB1
BALB/c
IgG2a(TH1)
IgG2a(TH2)
Leishmania cure
cell mediated immunity
Humoral immunity Death
ELISA
Figure  1  schematic  representation  of  nanoparticle  production  and  assessment 
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Table 1 Nature and composition of the different materials injected into BALB/c mice to assess type and severity of immune response
Group Injection type Injections (n) Aim of injection
1 PBs 3 Negative control
2 sLA + cFA 3 Positive control
3 empty nanoparticles 3 Immunogenicity of chitosan nanoparticles
4 cFA 3 comparison with chitosan adjuvant
5 sLA 3 comparison with sODB1 immunogenicity
6 sODB1 3 Immunogenicity of sODB1
7 cFA + sODB1 3 Immunogenicity of sODB1 with Freund’s 
adjuvant
8 Nanoparticles containing sODB1  3 Immunogenicity of sODB1 in nanoparticles
9 Nanoparticles containing sLA 3 comparison with nanoparticles 
containing sODB1
10 Nanoparticles containing sODB1 1 comparison with three nanoparticle 
doses – ability for sustained release
11 cFA + sODB1 1 comparison with single dose  
of nanoparticles 
containing sODB1
12 sODB1 1 comparison with single dose  
of nanoparticles 
containing sODB1
Abbreviations: cFA, complete Freund’s adjuvant; sODB1, superoxide dismutase B1; sLA, soluble Leishmania antigen; PBs, phosphate-buffered saline.
Three weeks after the final injection, blood samples were 
collected using the retro-orbital collection method.23 A hepa-
rinized microhematocrit tube was inserted carefully into the 
eye cavity, and a 0.2 mL blood sample was taken from each 
mouse. Serum was separated by centrifuging at 5000 rpm for 
5 minutes and stored at −70°C for further analysis.
Soluble Leishmania antigens were prepared from station-
ary-phase promastigotes of L. major (IR75), harvested after 
five passages, washed three times in ice-cold phosphate-
buffered saline (PBS; pH 7.2), and finally suspended in PBS 
buffer at a concentration of 1 × 107 cfu/mL. The suspension 
was sonicated five times, each step for 30 seconds and, 
between each step, the samples were kept for 30 seconds 
on ice and the lysate centrifuged at 12,000 g for 15 minutes 
at 4°C. After centrifuging, the supernatant was collected and 
the protein concentrations were estimated by the Bradford 
method. The extracted proteins were kept at −70°C and used 
as a positive control as needed.
enzyme-linked immunosorbent assay
In this study, 96-well flat-bottomed Maxisorb plates (NUNC, 
Denmark) were coated at 4°C overnight with 50 µL/well of 
SODB1 at 2 µg/mL in PBS. The plates were washed with 
300 µL of PBS containing 0.05% Tween 20 (PBS/T20) 
three times. They were then blocked for 1.5 hours at 37°C 
with 200 µL/well of 1% bovine serum albumin in PBS. 
Plates were washed with PBS/T20 twice. After that, serum 
samples were diluted to 1:500 with PBS (according to the 
initial setup) and applied to plates. The plates were incubated 
at 37°C for two hours and washed with 300 µL of PBS/T20 
four times. Horseradish peroxidases-conjugated antibodies 
were then added for one hour at 37°C using a 1:10000 dilu-
tion for rabbit antimouse IgG1 and a 1:2000 dilution for goat 
antimouse IgG2a. The plates were washed with 300 µL of 
PBS/T20 six times, 100 µL of tetramethylbenzidine substrate 
was added, and the plate was kept in the dark until the blue 
color of the PBS wells (negative control) began to appear. 
The reaction was stopped with 50 µL of 1 N sulfuric acid, and 
the plates were read at 450 nm in a microplate reader (Model 
Synergy; Bio-Rad Laboratories, Hercules, CA).
statistical analysis
Statistical analysis was performed using the Student’s t-test. 
Differences were considered significant at P , 0.05.
Results and discussion
Physicochemical characterization  
and peptide association
Chitosan nanoparticles were developed using a simple and 
straightforward technique involving the addition of tripoly-
phosphate solution to chitosan solution at room temperature. 
The nanoparticles were formed by an ionotropic gelation 
method. This gelation happens immediately upon mixing 
of the two phases through intermolecular and intramolecular 
linkage between negatively charged tripolyphosphates (pH 8) 
and positively charged chitosan amino groups (pH 4).24International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Because the isoelectric pH of SODB1 is 6.31,10 SODB1 
is better associated with the nanoparticles when dissolved in 
alkaline sodium tripolyphosphate solution. This is attributed 
to the ionic interaction between the negatively charged protein 
in the sodium tripolyphosphate solution and chitosan upon 
mixing. Other forces, including hydrogen bonding and hydro-
phobic forces, could be involved in the association process. 
The conditions for formation of high yield nanoparticles of a 
particular nanometric size may vary significantly depending 
on the purity, acid salt, and molecular weight of the chitosan 
used. Consequently, the formulation parameters should be 
optimized for each individual chitosan type.25 We examined 
high-, medium-, and low-molecular-weight chitosan for 
nanoparticle preparation and found that low molecular weight 
chitosan was able to make appropriately sized nanoparticles, 
so this was subsequently used to prepare nanoparticles 
within an appropriate size range. After several experiments 
based on similar studies,17,18 and preparation of more than 
31 formulations containing different ratios of chitosan and 
tripolyphosphate, formulation with an adequate size range 
of approximately 250–300nm was considered for further 
studies. Therefore, formulation 15 in Table 2 was chosen for 
our loading study. It has been claimed that antigen-containing 
nanoparticles greater than 225 nm in diameter tend to induce 
TH1 cytokines, whereas nanoparticles less than 155 nm are 
more likely to induce TH2-cytokines.14 Therefore, the size of 
the nanoparticles should be adjusted to 250–300 nm, so that 
they can be effectively phagocytosed by macrophages after 
injection, and migrate to their target (ie, the lysosome of the 
macrophage) to stimulate the immune system against the   
parasite. The association efficiency was then measured accord-
ing to the formula described in the Methods section. To ensure 
that chitosan showed no interference with the results of the 
protein assay using the Bradford method, protein-unloaded 
nanoparticles (containing chitosan and tripolyphosphate) were 
used as a blank solution in the spectrophotometric assay. The 
results are presented in Table 2.
SODB1-loaded nanoparticles showed a positive zeta 
potential of about +17 mV . This positive charge is in favor 
of the vaccine formulation, and the chances of positively 
charged nanoparticles are higher than negative charged or 
neutral nanoparticles for phagocytosis.26 Transmission elec-
tron microscopy of the nanoparticles identified 250–300 nm 
nanoparticles, the morphology of which is shown in   Figure 2. 
In summary, chitosan nanoparticles obtained by ionic cross-
linking with tripolyphosphate display some attractive features 
which render them promising carriers for the delivery of 
antigens. These features include ease of formation, a very 
homogeneous and adjustable size from 200 nm up to 1 mm, 
a positive surface charge that can be conveniently modulated, 
a good capacity for association with peptides, proteins, vac-
cines, oligonucleotides, and plasmids, release of the associated 
molecules at different rates depending on the composition of 
the particles, and, finally, retention of integrity and activity 
of the associated compounds following freeze-drying and 
reconstitution.25
Immunogenicity
Because leishmaniasis is an intracellular infection, it 
should be controlled by cell-mediated immunity. T cell 
Table 2 Concentration and volume ratios of chitosan and tripolyphosphate and resulting nanoparticle sizes and loading efficiency
Formulation Chitosan 
concentration (%)
Chitosan 
volume (mL)
TPP 
volume (mL)
Particle 
size (nm)
LE (%)
1 0.1 7 2.5 180 + 56 56 + 8
2 0.2 3 1.2 433 + 188 22 + 4
3 0.2 6.5 2.5 200 + 44 68 + 7
4 0.2 6.5 2.5   59 + 22 51 + 11
5 0.2 6.5 2.5 600 + 214 73 + 6
6 0.2 6.5 2.5 102 + 43 42 + 9
7 0.3 7.5 2.5 140 + 22 62 + 5
8 0.3 8 4 332 + 102 64 + 6
9 0.3 8 4 401 + 62 33 + 5
10 0.3 8 4 386 + 188 27 + 7
11 0.3 6.5 2.5 850 + 164 69 + 5
12 0.3 6.5 2.5 670 + 157 53 + 14
13 0.3 6.5 2.5 800 + 253 64 + 15
14 0.6 7.5 5 298 + 73 75 + 9
15* 0.6 7.5 5 255 + 45 72 + 12
Note: *Formulation selected for further study.
Abbreviations: LE, loading efficiency; TPP, tripolyphosphate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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responses and cytokine-induced macrophage activation are 
  determinants of cell-mediated immunity.27 Resistance to 
leishmaniasis is associated with the activation of TH1 CD4+ 
and CD8+ T cells, leishmanial antigens which can be picked 
up by antigen-presenting cells (dendritic and Langerhans 
cells) that transfer to CD4+ and CD8+ T cells inducing pro-
duction of different cytokines (IL22, IFN-γ, and granulocyte 
macrophage colony-stimulating factor), thereby activating 
macrophages to destroy intracellular parasites (cell-mediated 
immunity) through a nitric oxide-mediated mechanism.2 
Conversely, the activation of TH2 cells (humoral immunity) 
results in increased parasite survival and exacerbation of 
lesions because of the macrophage-suppressive actions of 
TH2 cytokines, notably IL-4.28 In mice, IgG2a produced 
from TH1 cells indicates cell-mediated immunity, and IgG1 
produced from TH2 cells indicates humoral immunity.29 
Therefore, the balance between TH1 and TH2 cells (TH1/TH2 
ratio) that influences the outcome of leishmaniasis can be 
represented as the IgG2a/IgG1 ratio.
The results of the enzyme-linked immunosorbent assay 
performed on sera from the 12 groups of mice are presented 
and compared in Figures 3 and 4. These show that SODB1 is 
immunogenic (significantly different from negative controls, 
P , 0.05), and are in agreement with the theory that virtually 
any parasite protein may act as an antigen, regardless of its 
location in the parasite, because T cells are able to   recognize 
peptides derived from cytosolic proteins bound in the major 
histocompatibility complex Class I groove or peptides 
derived from the lysosomal compartment bound in the major 
histocompatibility complex Class II groove on the antigen-
presenting cell surface.13 Comparison of the immunogenicity 
of SODB1 and soluble Leishmania antigens showed that, 
although SODB1 is less immunogenic than soluble Leish-
mania antigens, the pathway that SODB1 stimulates in the 
immune system is towards cellular immunity derived from 
the IgG2a/IgG1 ratio. SODB1 immunogenicity should be 
directed towards cellular immunity that is effective against 
leishmaniasis. The finding that chitosan nanoparticles con-
taining SODB1 induce a stronger response towards cellular 
immunity and parasite eradication than SODB1 alone in PBS 
and other control groups is logical. A significant difference 
(P , 0.05) was observed in the amount of IgG2a in compari-
son with the other groups, except for the soluble Leishmania 
antigen-loaded nanoparticle group. The IgG2a/IgG1 ratio 
was significantly higher (P , 0.05) for the SODB1-loaded 
nanoparticle group compared with the other groups.
Chitosan not only acts as an adjuvant and activates the 
immune system, but also increases antigen size, and activates 
the immune system more strongly by its ability to produce nano-
particles. This indicates that it would be a good substitute for a 
simple antigenic vaccine (purified or recombinant).
The ability of chitosan nanoparticles to sustain the release 
of SODB1 is evident when comparing triple doses and single 
doses of SODB1 nanoparticles. Statistical analysis showed 
that there was no significant difference between these two 
dose regimens (P . 0.05), and that both can stimulate the 
immune system efficiently toward cellular immunity against 
leishmaniasis. This property induces long-term activation of 
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the immune system, which suggests that a single dose vac-
cine is   feasible.   Comparison of a single dose of SODB1 alone 
with a single dose of SODB1   nanoparticles indicates that the 
pure peptide cannot   stimulate an adequate immune system 
response.   Furthermore, comparison of single dose Freund’s 
  adjuvant + SODB1 with SODB1 nanoparticles showed that 
the nanoparticles stimulate cellular immunity more effectively 
(P , 0.05). Moreover, chitosan is a biodegradable, safe, and a 
relatively low-cost polymer, so that it is a promising candidate 
for vaccine delivery.
Because SODB1 has a similar structure to many protozo-
ans, it could be used as a potential vaccine for other protozoan 
infections, including malaria, trypanosomiasis, trichomoniasis, 
and toxoplasmosis. The structure of protozoan superoxide dis-
mutase is different from that of human superoxide dismutase, 
so there would be no risk of an autoimmune response.
From the pharmaceutical point of view, mass production of 
recombinant particulate antigen is safer and more accurate with 
modern recombination techniques, and better controlled with 
Good Manufacturing Practice rules than mass production of 
killed or dangerously modified micro-organisms. For example, 
active substance assay (for dose adjustment) is possible for 
recombinant antigens and macromolecules (nanoparticles) by 
new chemical/biotechnological instrumentation, while for weak 
or dead microbes, the assay is complicated and imprecise.
Conclusion
Having demonstrated the efficacy of nanoparticulate deliv-
ery of a vaccine subunit, we formulated SODB1 in chitosan 
nanoparticles. Our data show that chitosan is able to increase 
SODB1 immunogenicity in BALB/c mice, not only by 
increasing its size and better stimulation of the immune 
system, but also by the adjuvant properties of chitosan. 
Both single-dose and triple-dose vaccination with SODB1 
chitosan-loaded nanoparticles showed identical results, and 
were found to be more effective in inducing cell-mediated 
immunity (TH1 cells that is responsible for Leishmania 
eradication and could be indicated by IgG2a in mice) than 
control and other groups which received the soluble form of 
SODB1 antigen. The present findings also confirm the pos-
sibility of a single dose nanovaccine for leishmaniasis and 
similar protozoan diseases. Moreover, chitosan nanoparticles 
can improve protein stability in production, transportation, 
and administration, and a potentially longer shelf life. Also, 
chitosan is safe, biodegradable, and cost-effective. Finally, 
the ionotropic gelation method is suitable for protein loading 
in nanoparticles which exhibited high loading efficiency in 
this study.
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